Camostat

• Description :

  Camostat is an orally active trypsin inhibitor. Camostat can reduce pancreatic fibrosis induced by repeated administration of superoxide dismutase inhibitors in rats, and decrease the proliferation and activation of pancreatic stellate cells (PSCs) [1].

• CAS Number :

  [59721-28-7]

• UNSPSC :

  12352005

• Target :

  Ser/Thr Protease

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/camostat.html

• Concentration :

  10mM

• Purity :

  99.42

• Solubility :

  DMSO : 175 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC=C(NC(N)=N)C=C1)OC2=CC=C(CC(OCC(N(C)C)=O)=O)C=C2

• Molecular Formula :

  C20H22N4O5

• Molecular Weight :

  398.41

• References & Citations :

  [1]Emori Y, et al. Camostat, an oral trypsin inhibitor, reduces pancreatic fibrosis induced by repeated administration of a superoxide dismutase inhibitor in rats. J Gastroenterol Hepatol. 2005 Jun;20 (6) :895-9.

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 4

• Citation 01 :

  J Virol. 2025 Aug 11:e0105525.|PLoS Pathog. 2025 Oct 14;21 (10) :e1013593.|Am J Physiol Renal Physiol. 2024 Aug 1;327 (2) :F265-F276.|Antiviral Res. 2023 Jun:214:105606.|Biochem Pharmacol. 2023 Jul:213:115617.|Biosaf Health. 2022 Feb;4 (1) :38-44.|Cell Discov. 2021 Dec 14;7 (1) :119.|Cell Prolif. 2025 May 15:e70060.|Cell Rep Med. 2022 Sep 20;3 (9) :100743.|Cell. 2023 Feb 16;186 (4) :850-863.e16.|EBioMedicine. 2023 Sep:95:104753.|Emerg Microbes Infect. 2022 Dec;11 (1) :2275-2287.|Eur J Med Chem. 2021 Nov 15:224:113683.|Eur J Pharmacol. 2022 Mar 15:919:174795.|Eur J Pharmacol. 2023 Jan 5:938:175394.|Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Transmissores de Hematozoários. 2020 Sep.|J Virol. 2023 May 31;97 (5) :e0032423.|J Virol. 2025 Nov 18:e0127425.|mBio. 2022 Dec 20;13 (6) :e0256622.|Nat Chem Biol. 2022 Sep;18 (9) :963-971.|Nat Commun. 2022 Jul 26;13 (1) :4331.|Nat Commun. 2022 Mar 17;13 (1) :1444.|Nat Commun. 2024 Jul 3;15 (1) :5606.|Nat Commun. 2024 Oct 9;15 (1) :8728.|Nat Commun. 2025 Jul 7;16 (1) :6241.|Nat Microbiol. 2024 Sep;9 (9) :2383-2394.|Nat Microbiol. 2025 Oct 30, 10 (11) :2860-2874.|Nature. 2022 Mar;603 (7902) :693-699.|Nucleic Acids Res. 2021 Jan 8;49 (D1) :D1113-D1121.|Proc Natl Acad Sci U S A. 2022 Jan 25;119 (4) :e2117576119.|Res Sq. 2023 Sep 11:rs.3.rs-3220157.|Res Sq. 2024 Nov 21.|Research Square Preprint. 2022 Jan.|Sci Adv. 2023 Jan 20;9 (3) :eadd3867.|Sci China Life Sci. 2025 Oct 24.|Sci Signal. 2024 Aug 20;17 (850) :eadn3785.|Signal Transduct Target Ther. 2022 Mar 11;7 (1) :83.|SSRN. 2020 Jun.|SSRN. 2024 Jan 26.|SSRN. 2024 Jul 11.|Utrecht University. CENTER FOR CELL IMAGING. 2022 Jul.|Viruses. 2022 Feb 8;14 (2) :353.